ChiCTR2500104498 版本V1.0 版本创建时间2025/06/18 10:06:27 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500104498 

最近更新日期:

Date of Last Refreshed on:

2025-06-18 10:06:09 

注册时间:

Date of Registration:

2025-06-18 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

胸腔镜经剑突下入路与经肋间入路前纵隔肿物切除术治疗效果的回顾性队列研究

Public title:

Effects of endoscopic mediastinal tumor resection via subxiphoid and intercostal approaches: a retrospective cohort study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

胸腔镜经剑突下入路与经肋间入路前纵隔肿物切除术治疗效果的回顾性队列研究

Scientific title:

Effects of endoscopic mediastinal tumor resection via subxiphoid and intercostal approaches: a retrospective cohort study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

柴燕飞 

研究负责人:

柴燕飞 

Applicant:

Yanfei Chai 

Study leader:

Yanfei Chai 

申请注册联系人电话:

Applicant telephone:

+86 139 7572 1834

研究负责人电话:

Study leader's
telephone:

+86 139 7572 1834

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

317516933@qq.com

研究负责人电子邮件:

Study leader's E-mail:

317516933@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

东莞市万江街道新谷涌万道路78号

研究负责人通讯地址:

东莞市万江街道新谷涌万道路78号

Applicant address:

No. 78, Wanda Road, Xingu Village, Wanjiang District, Dongguan City

Study leader's address:

No. 78, Wanda Road, Xingu Village, Wanjiang District, Dongguan City

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

南方医科大学第十附属医院(东莞市人民医院)

Applicant's institution:

The Tenth Affiliated Hospital of Southern Medical University (Dongguan People’s Hospital)

研究负责人所在单位:

南方医科大学第十附属医院(东莞市人民医院)

Affiliation of the Leader:

The Tenth Affiliated Hospital of Southern Medical University (Dongguan People’s Hospital)

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KYKT2025-041

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

东莞市人民医院医学伦理委员会

Name of the ethic committee:

Ethics Committee of Dongguan People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-05-17 00:00:00

伦理委员会联系人:

袁领勤

Contact Name of the ethic committee:

Lingqin Yuan

伦理委员会联系地址:

东莞市万江街道新谷涌万道路78号

Contact Address of the ethic committee:

No. 78, Wanda Road, Xingu Village, Wanjiang District, Dongguan City

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 769 2863 6353

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

南方医科大学第十附属医院(东莞市人民医院)

Primary sponsor:

The Tenth Affiliated Hospital of Southern Medical University (Dongguan People’s Hospital)

研究实施负责(组长)单位地址:

东莞市万江街道新谷涌万道路78号

Primary sponsor's address:

No. 78, Wanda Road, Xingu Village, Wanjiang District, Dongguan City

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

Country:

China

Province:

Guangdong

City:

单位(医院):

南方医科大学第十附属医院(东莞市人民医院)

具体地址:

东莞市万江街道新谷涌万道路78号

Institution
hospital:

The Tenth Affiliated Hospital of Southern Medical University (Dongguan People’s Hospital)

Address:

No. 78, Wanda Road, Xingu Village, Wanjiang District, Dongguan City

经费或物资来源:

Source(s) of funding:

None

研究疾病:

纵隔与胸膜疾病  

Target disease:

Mediastinal and pleural diseases

研究疾病代码:

H0114

Target disease code:

H0114

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

比较胸腔镜经剑突入路与经肋间下入路行前纵隔肿物切除术的安全性和可行性。  

Objectives of Study:

The present study aimed to assess the safety and feasibility of the subxiphoid approach and the lateral intercostal approach for anterior mediastinal tumors resection through video-assisted thoracic surgery (VATS).

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)诊断为前纵隔肿物,根据CT评估可完全切除。 (2)肿物包膜完整,无血管、心包侵犯。 (3)术前检查未见明显手术禁忌。

Inclusion criteria

(1) An anterior mediastinal tumor, which could be completely rescted based on the CT assessment. (2) The tumor has an intact capsule with no invasion of blood vessels or pericardium. (3) No obvious surgical contraindications were found during preoperative examination.

排除标准:

(1)既往胸部手术史; (2)肿物侵及邻近血管、肺叶或心包等重要组织; (3)合并其他影响手术的心肺疾病。

Exclusion criteria:

(1) Previous history of chest surgery; (2) Tumor invasion of adjacent vital tissues such as blood vessels, lung lobes or pericardium; (3) Coexistence of other heart and lung diseases that affect the surgery.

研究实施时间:

Study execute time:

From 2025-07-01 00:00:00 To 2025-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-07-01 00:00:00 To 2025-08-31 00:00:00

干预措施:

Interventions:

组别:

经剑突下入路组

样本量:

42

Group:

The subxiphoid approach group

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

组别:

经肋间入路组

样本量:

181

Group:

The lateral intercostal approach group

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

南方医科大学第十附属医院(东莞市人民医院) 

单位级别:

三甲 

Institution
hospital:

The Tenth Affiliated Hospital of Southern Medical University (Dongguan People’s Hospital)

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

手术时间

指标类型:

主要指标

Outcome:

operation time

Type:

Primary indicator

测量时间点:

手术中

测量方法:

Measure time point of outcome:

during sugery

Measure method:

指标中文名:

手术出血量

指标类型:

主要指标

Outcome:

blood loss

Type:

Primary indicator

测量时间点:

手术中

测量方法:

Measure time point of outcome:

during sugery

Measure method:

指标中文名:

术后胸管留置时间

指标类型:

主要指标

Outcome:

duration of drainage

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后疼痛评分

指标类型:

主要指标

Outcome:

pain scores

Type:

Primary indicator

测量时间点:

术后第1天、第2天、第3天、第7天、第30天

测量方法:

视觉模拟评分法(visual analogue scale,VAS),0分表示无痛,10分代表难以忍受的最剧烈的疼痛。

Measure time point of outcome:

day after the operation on day 1,2,3,7,30

Measure method:

The Visual Analogue Scale (VAS) is used to rate pain. A score of 0 indicates no pain, while a score of 10 represents the most intense and unbearable pain.

指标中文名:

术后并发症

指标类型:

次要指标

Outcome:

postoperative complications

Type:

Secondary indicator

测量时间点:

手术后当天至术后30天

测量方法:

Measure time point of outcome:

From the day after the surgery to 30 days after the surgery

Measure method:

指标中文名:

术后总引流量

指标类型:

次要指标

Outcome:

total drainage volume

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后住院时间

指标类型:

次要指标

Outcome:

postoperative hospital stay

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

相关研究结果发表后联系作者获取

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

After the publication of the relevant research results

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

使用病例记录表采集数据,汇总后做为电子档案进行管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Collect data using case record forms, and then summarize them for management as an electronic archive.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-06-18 10:06:09